Literature DB >> 10968249

Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy.

H Azuma, M Oshima, K Ito, A Okuno, I Kawabata, K Banba, H Murahashi, T Sekine, Y Kato, K Ikebuchi, H Ikeda.   

Abstract

Interleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10968249     DOI： 10.1007/pl00008395

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  7 in total

1.  The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study.

Authors:  Nan Chen; Zhi-Yong Zhang; Da-Wei Liu; Wei Liu; Xue-Mei Tang; Xiao-Dong Zhao
Journal:  Eur J Pediatr       Date:  2015-04-16       Impact factor: 3.183

Review 2.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

3.  IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function.

Authors:  Jordan S Orange; Sumita Roy-Ghanta; Emily M Mace; Saumya Maru; Gregory D Rak; Keri B Sanborn; Anders Fasth; Rushani Saltzman; Allison Paisley; Linda Monaco-Shawver; Pinaki P Banerjee; Rahul Pandey
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

4.  Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses.

Authors:  Jordan S Orange; Narayanaswamy Ramesh; Eileen Remold-O'Donnell; Yoji Sasahara; Louise Koopman; Michael Byrne; Francisco A Bonilla; Fred S Rosen; Raif S Geha; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

5.  Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma.

Authors:  Marco Catucci; Maria Carmina Castiello; Francesca Pala; Marita Bosticardo; Anna Villa
Journal:  Front Immunol       Date:  2012-07-18       Impact factor: 7.561

Review 6.  Signal Integration during T Lymphocyte Activation and Function: Lessons from the Wiskott-Aldrich Syndrome.

Authors:  Vinicius Cotta-de-Almeida; Loïc Dupré; Delphine Guipouy; Zilton Vasconcelos
Journal:  Front Immunol       Date:  2015-02-09       Impact factor: 7.561

Review 7.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.